Intellectual Property Industries

Bar Admissions

  • New York

Court Admissions

  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the Western District of New York
  • U.S. District Court for the Southern District of New York

Education

  • J.D., magna cum laude, Pace Law School, 2003
    Editor, Pace Law Review
  • Ph.D., Biochemistry, summa cum laude, University of California at Berkeley
  • B.S., Biology, magna cum laude, State University of New York at Albany
T +1 212.218.2298
F +1 212.218.2200
 

Robert S. Schwartz, Ph.D.

Partner

Robert Schwartz, Ph.D. focuses his practice on biotechnology and pharmaceutical patent litigation, USPTO contested cases, technical advising, and patentability and non-infringement opinions. His primary focus is in the areas of biotechnology, particularly protein biochemistry, cell biology, molecular biology, genomics, proteomics and the chemical arts. Some of the technologies he has worked with include transgenic mice, antibodies, nucleotide prodrugs, enzyme inhibitors, cell growth factors, receptor antagonists, nucleotide sequencing technology and vaccines.

While in law school Bob was an editor of the Pace Law Review. Prior to becoming an attorney, he was an Associate Professor of Medicine at the Albert Einstein College of Medicine, Bronx, NY, and a Staff Scientist at Children's Hospital Oakland Research Institute (CHORI) where he was a Principal Investigator of grant-funded biomedical research in areas including hereditary anemias, malaria and diabetes. Bob has published over 40 scientific articles and book chapters in peer-reviewed journals, as well as numerous articles relating to subject matter patentability, biologics and biosimilars. Bob is a frequent speaker at conferences on topics relating to biologics and biosimilars.

Representative Clients

  • Advaxis
  • AstraZeneca
  • Brisol-Myers Squibb
  • Regeneron
  • Sanofi

Significant Matters

  • Columbia University against Illumina in a patent litigation relating to DNA sequencing products.
  • Gilead against Teva in an ANDA patent litigation relating to Atripla® and Truvada® products.
  • GlaxoSmithKline against Teva in an ANDA patent litigation relating to GlaxoSmithKline’s Avodart® product.
  • Bristol-Myers Squibb against Repligen and Zymogenetics in patent litigations relating to Bristol-Myers Squibb’s Orencia® product.
  • GlaxoSmithKline against Dr. Reddy’s Laboratories, Cobalt Pharmaceuticals and Spectrum Pharmaceuticals in ANDA patent litigations relating to GlaxoSmithKline’s Imitrex® product.
  • G.D. Searle and Pharmacia against the University of Rochester in a patent litigation relating to G.D. Searle and Pharmacia’s Celebrex® product.
  • Regeneron against Genentech in a patent litigation relating to Eylea®.